MCID: PLS006
MIFTS: 51

Plasmodium Vivax Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Vivax Malaria

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 12 15 17 32
Malaria, Vivax 44 70
Malaria by Plasmodium Vivax 12
Vivax Malaria 12
Malaria Vivax 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12978
ICD9CM 34 084.1
MeSH 44 D016780
NCIt 50 C34800
SNOMED-CT 67 27052006
UMLS 70 C0024537

Summaries for Plasmodium Vivax Malaria

Disease Ontology : 12 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary : Plasmodium Vivax Malaria, also known as malaria, vivax, is related to glucosephosphate dehydrogenase deficiency and plasmodium ovale malaria. An important gene associated with Plasmodium Vivax Malaria is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs tafenoquine and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include spleen, liver and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Plasmodium Vivax Malaria

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 718)
# Related Disease Score Top Affiliating Genes
1 glucosephosphate dehydrogenase deficiency 31.7 G6PD CYP2D6 ACKR1
2 plasmodium ovale malaria 31.0 G6PD CYP2D6
3 disseminated intravascular coagulation 30.9 TNF THBD IL6 IL10
4 pulmonary edema 30.8 TNF IL1B IL10 ICAM1
5 cardiogenic shock 30.7 TNF IL6
6 acute pancreatitis 30.7 TNF IL6 IL1B IL10
7 adult respiratory distress syndrome 30.7 TNF THBD SELE IL6 IL1B IL10
8 bacterial infectious disease 30.6 TNF IL6 IL1B IL10 IFNG
9 exanthem 30.6 TNF IL6 IL2 IL1B IL10 IFNG
10 neurosyphilis 30.6 IL10 CXCL10
11 syphilis 30.5 TNF IL6 IFNG CD40LG
12 bilirubin metabolic disorder 30.5 TNF IL6 IL2 IL1B G6PD CYP2D6
13 bronchiolitis obliterans 30.5 TNF IL6 IL10 IFNG
14 plasmodium falciparum malaria 30.5 TNF SELE IL6 IL10 IFNG ICAM1
15 disease by infectious agent 30.5 TNF IL6 IL2 IL1B IL10 IFNG
16 myelitis 30.4 TNF IL6 IL10
17 intracranial hypertension 30.4 TNF IL1B CXCL10
18 lymphopenia 30.4 IL6 IL2 IL10 IFNG
19 urticaria 30.4 TNF SELE IL6 IL10
20 purpura 30.4 TNF THBD IL6 IL10 IFNG
21 cryptococcosis 30.4 TNF IL10 IFNG
22 hepatitis e 30.4 TNF IFNG CD40LG
23 chickenpox 30.4 TNF IL6 IL2 IL10 IFNG
24 vaccinia 30.3 TNF IL6 IL2 ICAM1
25 mycobacterium tuberculosis 1 30.3 TNF IL10 IFNG CXCL10
26 glomerulonephritis 30.3 VCAM1 IL1B ICAM1 CD40LG
27 dengue hemorrhagic fever 30.3 TNF IL6 IL10 IFNG ICAM1
28 ascaris lumbricoides infection 30.3 IL6 IL1B IFNG
29 acute myocarditis 30.3 TNF IL10 CD40
30 crescentic glomerulonephritis 30.3 VCAM1 SELE ICAM1
31 echinococcosis 30.2 TNF IL6 IL10 IFNG
32 chikungunya 30.2 TNF IL6 IL1B
33 neutropenia 30.2 TNF IL6 IL2 IL1B IL10
34 lyme disease 30.2 TNF IL6 IL1B CD40LG
35 optic neuritis 30.2 TNF IL6 IL1B IL10 CXCL10
36 yellow fever 30.1 IL6 IL1B CXCL10
37 hemolytic anemia 30.0 TNF THBD IL2 IL10 IFNG G6PD
38 brucellosis 30.0 TNF IL6 IL2 IL10 IFNG
39 leptospirosis 30.0 TNF IL6 IL2 IL1B IL10 IFNG
40 arteriovenous malformation 29.8 TNF SELE IL6 IL1B ANGPT2
41 typhoid fever 29.8 TNF THBD IL6 IL1B IFNG
42 appendicitis 29.8 TNF IL6 IL2 IL1B IL10 IFNG
43 dengue disease 29.7 VCAM1 TNF IL10 IFNG ICAM1 CD40LG
44 peripheral nervous system disease 29.7 TNF IL6 IL2 IL1B IL10 IFNG
45 neuritis 29.7 VCAM1 TNF IL6 IL1B IL10 IFNG
46 viral hepatitis 29.6 TNF IL6 IL2 IL1B IL10 IFNG
47 meningitis 29.6 TNF IL6 IL2 IL1B IL10 IFNG
48 diarrhea 29.4 TNF IL6 IL2 IL1B IL10 IFNG
49 bronchiolitis 29.1 TNF IL6 IL4R IL1B IL10 IFNG
50 demyelinating disease 29.1 TNF IL6 IL2 IL1B IL10 IFNG

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria

Symptoms & Phenotypes for Plasmodium Vivax Malaria

GenomeRNAi Phenotypes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CD40LG IL10 IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ICAM1 IL10 IL1B IL2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 DHFR ICAM1

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 ANGPT2 CD40LG CXCL10 DDX39B DHFR G6PD
2 cardiovascular system MP:0005385 10.41 ANGPT2 CD40LG CXCL10 DHFR G6PD ICAM1
3 homeostasis/metabolism MP:0005376 10.41 ACKR1 ANGPT2 CD40 CD40LG CXCL10 DDX39B
4 hematopoietic system MP:0005397 10.39 ANGPT2 CD40 CD40LG CXCL10 DHFR G6PD
5 immune system MP:0005387 10.33 ACKR1 ANGPT2 CD40 CD40LG CXCL10 DHFR
6 growth/size/body region MP:0005378 10.29 DHFR G6PD ICAM1 IFNG IL10 IL1B
7 endocrine/exocrine gland MP:0005379 10.19 ANGPT2 CD40 CD40LG ICAM1 IFNG IL10
8 mortality/aging MP:0010768 10.19 ANGPT2 CD40LG CXCL10 DDX39B DHFR G6PD
9 digestive/alimentary MP:0005381 10.16 ANGPT2 ICAM1 IFNG IL10 IL2 IL4R
10 integument MP:0010771 10.15 ANGPT2 CD40LG DHFR ICAM1 IFNG IL10
11 liver/biliary system MP:0005370 9.97 DHFR IFNG IL10 IL2 IL4R IL6
12 nervous system MP:0003631 9.77 CD40 CD40LG CXCL10 DHFR G6PD ICAM1
13 neoplasm MP:0002006 9.7 ICAM1 IFNG IL10 IL1B IL2 IL6
14 respiratory system MP:0005388 9.28 ANGPT2 IFNG IL10 IL2 IL4R IL6

Drugs & Therapeutics for Plasmodium Vivax Malaria

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tafenoquine Approved, Investigational Phase 4 106635-80-7 115358
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Primaquine Approved Phase 4 90-34-6 4908
4
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
5
Artemether Approved Phase 4 71963-77-4 9796294 119380 68911
6
Lactitol Approved, Investigational Phase 4 585-86-4 157355
7
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
8 Analgesics, Non-Narcotic Phase 4
9 Antiviral Agents Phase 4
10 Analgesics Phase 4
11 Anthelmintics Phase 4
12 Anti-Inflammatory Agents Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Artemisinine Phase 4
15 Artemisinins Phase 4
16 Artemether, Lumefantrine Drug Combination Phase 4
17
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
19 Orange Approved Phase 3
20
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
21
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
22
Dapsone Approved, Investigational Phase 3 80-08-0 2955
23
Dihydroartemisinin Approved, Experimental, Investigational Phase 3 71939-50-9 6918483
24
Piperaquine Approved, Experimental, Investigational Phase 3 4085-31-8 5079497
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26
Chlorproguanil Investigational Phase 3 537-21-3 9571037 151170
27
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
28
Pyronaridine Investigational Phase 3 74847-35-1 5485198
29 Folic Acid Antagonists Phase 3
30 Vitamin B9 Phase 3
31 Vitamin B Complex Phase 3
32 Folate Phase 3
33 Fanasil, pyrimethamine drug combination Phase 3
34 Anti-Bacterial Agents Phase 3
35
Tinidazole Approved, Investigational Phase 2 19387-91-8 5479
36
Cobicistat Approved Phase 2 1004316-88-4
37 Alkylating Agents Phase 2
38 Vaccines Phase 2
39
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
40
Moxifloxacin Approved, Investigational Phase 1 354812-41-2, 151096-09-2 152946
41 Pharmaceutical Solutions Phase 1
42 diuretics Phase 1
43 Immunologic Factors Phase 1
44 Freund's Adjuvant Phase 1
45 Adjuvants, Immunologic Phase 1
46 Norgestimate, ethinyl estradiol drug combination Phase 1
47
Permethrin Approved, Investigational 52645-53-1 40326
48 Liver Extracts
49 Antibodies
50 Immunoglobulins

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
3 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
4 Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
5 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Completed NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
6 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Active, not recruiting NCT03916003 Phase 4 primaquine
7 Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia Not yet recruiting NCT04704999 Phase 4 Tafenoquine;Chloroquine;Artemether 20 mg-Lumefantrine 120 mg
8 Short Course Radical Cure of P.Vivax in Nepal- a Randomized Controlled Trial Not yet recruiting NCT04079621 Phase 4 primaquine
9 A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
10 Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations Terminated NCT03337152 Phase 4 primaquine;chloroquine + primaquine
11 Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine. Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
12 Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia Unknown status NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
13 A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
14 Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
15 Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria Completed NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
16 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
17 Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
18 Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
19 A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
20 Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
21 A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria. Completed NCT00158587 Phase 3 primaquine
22 An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
23 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
24 Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Completed NCT00158548 Phase 3 SP, chloroquine, amodiaquine, primaquine, artesunate
25 Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon Completed NCT01845701 Phase 3 Artesunate-Amodiaquine;Dihydroartemisinine-Piperaquine;Artemether-lumefantrine combination
26 Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
27 An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria Recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
28 Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients Not yet recruiting NCT04411836 Phase 3 Tafenoquine;Primaquine
29 A Phase III Randomised, Double-blind, Double-dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients in Korea With Acute Plasmodium Vivax Malaria Terminated NCT04368910 Phase 3 Pyronaridine - artesunate;Chloroquine
30 A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
31 An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria Completed NCT02563496 Phase 2 Tafenoquine;Chloroquine
32 A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
33 Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
34 A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
35 A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
36 A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
37 Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
38 Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Completed NCT00811096 Phase 2 Tinidazole;chloroquine
39 A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 in Healthy Adults Living in the UK Recruiting NCT04201431 Phase 1, Phase 2
40 A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK Recruiting NCT04009096 Phase 2
41 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients Recruiting NCT03529396 Phase 2 Chloroquine;Primaquine;Primaquine;Chloroquine;Primaquine
42 An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period Recruiting NCT04709692 Phase 2 (+)-SJ000557733 (SJ733)
43 Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers Not yet recruiting NCT04739917 Phase 2
44 Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Terminated NCT02110784 Phase 2 Eurartesim tablets
45 Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial Withdrawn NCT02696928 Phase 2 Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy)
46 Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States Completed NCT00935623 Phase 1
47 Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria Completed NCT00295581 Phase 1 PpPfs25/ISA51 & ScPvs25/ISA51
48 Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects Completed NCT01218932 Phase 1 A;B
49 A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax Completed NCT01780753 Phase 1 Primaquine
50 A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium Vivax Malaria Patients With Glucose-6-phosphate Dehydrogenase Deficiency Completed NCT01205178 Phase 1 Chloroquine;Primaquine;Tafenoquine

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 70 / NDF-RT 51 :


halofantrine
Halofantrine hydrochloride
Mefloquine
Mefloquine Hydrochloride
Primaquine
Primaquine Phosphate

Cochrane evidence based reviews: malaria, vivax

Genetic Tests for Plasmodium Vivax Malaria

Anatomical Context for Plasmodium Vivax Malaria

MalaCards organs/tissues related to Plasmodium Vivax Malaria:

40
Spleen, Liver, T Cells, Bone, Kidney, Neutrophil, Bone Marrow

Publications for Plasmodium Vivax Malaria

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 1141)
# Title Authors PMID Year
1
FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil. 54 61
20162434 2010
2
[Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day]. 54 61
15330059 2004
3
Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. 54 61
8036681 1994
4
Liver and kidney dysfunction, hypoglycemia, and thrombocytopenia in Plasmodium vivax malaria patients at a Colombian Northwest region. 61
33615000 2021
5
Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients. 61
32997351 2021
6
PvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon. 61
33801386 2021
7
Anti-malarial drug effects on parasite dynamics in vivax malaria. 61
33743731 2021
8
Complications of Sub-microscopic Plasmodium vivax Malaria among Orang Asli in Pos Lenjang, Kuala Lipis. 61
33797521 2021
9
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon. 61
33596478 2021
10
Modelling the impact of rapid diagnostic tests on Plasmodium vivax malaria in South Korea: a cost-benefit analysis. 61
33593755 2021
11
Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. 61
33543710 2021
12
Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India? 61
33619041 2021
13
Plasmodium vivax from Duffy-Negative and Duffy-Positive Individuals Shares Similar Gene Pool in East Africa. 61
33534886 2021
14
Clinicobiochemical Parameters and Predictors of Liver Disease in Hospitalized Asian Indian Pregnant Women in a Tertiary Care Center in Northern India. 61
33758702 2021
15
Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development. 61
33421653 2021
16
Retinopathy Secondary to Uncomplicated Plasmodium vivax Malaria. 61
33471916 2021
17
Efficacy Study of Chloroquine to Plasmodium vivax Malaria in Darimu and Bure Districts, Southwest Ethiopia. 61
33688214 2021
18
Antibody Dynamics for Plasmodium vivax Malaria: A Mathematical Model. 61
33387082 2021
19
Alternative Invasion Mechanisms and Host Immune Response to Plasmodium vivax Malaria: Trends and Future Directions. 61
33374596 2020
20
[Epidemiological and clinical aspects of diagnosis, treatment and prophylaxis of imported malaria cases in Russian Federation]. 61
33720609 2020
21
Relapse or reinfection: Classification of malaria infection using transition likelihoods. 61
32022247 2020
22
Misidentification of Plasmodium ovale as Plasmodium vivax malaria by a microscopic method: a meta-analysis of confirmed P. ovale cases. 61
33311528 2020
23
Prevalence and Clinical Presentation of COVID-19 among Healthcare Workers at a Dedicated Hospital in India 61
33247637 2020
24
Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study. 61
32415986 2020
25
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia. 61
33175835 2020
26
Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries. 61
33146932 2020
27
Study of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Genotype Polymorphism of G6PD B and G6PD (A+/A-) in Patients Treated for Plasmodium vivax Malaria in a Tertiary Care Hospital in North East India. 61
33214970 2020
28
Whole genome sequencing of Plasmodium vivax isolates reveals frequent sequence and structural polymorphisms in erythrocyte binding genes. 61
33044985 2020
29
Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. 61
32925910 2020
30
Efficacy and Safety of Pyronaridine-Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar. 61
32524960 2020
31
Plasmodium Vivax Malaria: Usual Illness with Dysregulated Immune Profile. 61
32996902 2020
32
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. 61
32892362 2020
33
Effects of IgG and IgM autoantibodies on non-infected erythrocytes is related to ABO blood group in Plasmodium vivax malaria and is associated with anemia. 61
32097712 2020
34
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria. 61
32433338 2020
35
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia. 61
32511702 2020
36
Mass radical treatment of a group of foreign workers to mitigate the risk of re-establishment of malaria in Sri Lanka. 61
32977809 2020
37
A case series of distal renal tubular acidosis, Southeast Asian ovalocytosis and metabolic bone disease. 61
32758154 2020
38
Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016. 61
32687027 2020
39
The changing risk patterns of Plasmodium vivax malaria in Greece due to climate change. 61
32683891 2020
40
Platelet disturbances correlate with endothelial cell activation in uncomplicated Plasmodium vivax malaria. 61
32687542 2020
41
Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial. 61
31604130 2020
42
Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis. 61
32036012 2020
43
Case Report: Primaquine Failure for Radical Cure of Plasmodium vivax Malaria in Gambella, Ethiopia. 61
32394882 2020
44
Diffuse alveolar hemorrhage due to Plasmodium vivax malaria. 61
32643646 2020
45
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. 61
32680522 2020
46
A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic Plasmodium berghei Parasite. 61
32560380 2020
47
Morphological and Transcriptional Changes in Human Bone Marrow During Natural Plasmodium vivax Malaria Infections. 61
32556188 2020
48
Primaquine for Plasmodium vivax malaria treatment - Authors' reply. 61
32593334 2020
49
Presence of additional Plasmodium vivax malaria in Duffy negative individuals from Southwestern Nigeria. 61
32590997 2020
50
Primaquine for Plasmodium vivax malaria treatment. 61
32593332 2020

Variations for Plasmodium Vivax Malaria

Expression for Plasmodium Vivax Malaria

Search GEO for disease gene expression data for Plasmodium Vivax Malaria.

Pathways for Plasmodium Vivax Malaria

Pathways related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 VCAM1 TNF IL6 IL4R IL2 IL1B
2
Show member pathways
13.91 TNF IL6 IL4R IL2 IL1B IL10
3
Show member pathways
13.79 TNF IL6 IL4R IL2 IL1B IL10
4
Show member pathways
13.63 TNF IL6 IL4R IL2 IL1B IL10
5
Show member pathways
13.53 TNF IL6 IL4R IL2 IL1B IL10
6
Show member pathways
13.42 VCAM1 TNF IL6 IL4R IL2 IL1B
7
Show member pathways
13.38 TNF IL6 IL4R IL2 IL1B IL10
8
Show member pathways
13.18 VCAM1 TNF SELE IL6 IL2 IL1B
9
Show member pathways
12.96 TNF IL6 IL2 IL1B IL10 IFNG
10
Show member pathways
12.92 TNF IL6 IL2 IL1B IFNG ICAM1
11
Show member pathways
12.82 TNF IL6 IL2 IL1B CD40LG CD40
12
Show member pathways
12.77 TNF IL4R IL2 IL10 IFNG CD40LG
13
Show member pathways
12.74 TNF IL1B IFNG CD40LG CD40
14
Show member pathways
12.73 TNF IL6 IL2 IL1B IL10 IFNG
15
Show member pathways
12.71 TNF IL6 IL4R IL2 IL1B IL10
16
Show member pathways
12.7 TNF IL6 IL2 IL1B IL10 IFNG
17 12.69 VCAM1 TNF IL2 IL1B IL10 IFNG
18
Show member pathways
12.53 IL6 IL4R IL2 IL10 IFNG
19
Show member pathways
12.47 TNF IL6 IL2 IL10 CXCL10 ACKR1
20
Show member pathways
12.47 TNF IL6 IL2 IL1B IFNG ICAM1
21 12.46 TNF IL6 IL2 ICAM1 CD40
22
Show member pathways
12.45 TNF IL6 IL1B IFNG CXCL10
23
Show member pathways
12.4 TNF IL6 IL2 IL1B IL10 IFNG
24
Show member pathways
12.4 TNF IL1B IL10 IFNG CD40LG CD40
25 12.37 TNF IL6 IL1B IL10 IFNG
26
Show member pathways
12.35 TNF IL6 IL2 IL1B IL10
27
Show member pathways
12.32 TNF IL6 IL1B IFNG CXCL10
28 12.27 VCAM1 SELE ICAM1 CD40LG CD40
29 12.26 TNF IL6 IL1B IL10
30 12.23 TNF IL6 IL2 IL1B IL10
31 12.21 VCAM1 TNF THBD SELE IL1B IFNG
32 12.17 VCAM1 ICAM1 CD40LG CD40
33 12.15 TNF IL6 IL2 IL10 IFNG
34 12.13 TNF IL6 IL2 IL1B IFNG ICAM1
35 12.1 VCAM1 TNF IL6 IL4R IL1B IL10
36 12.08 TNF IL6 IL1B IL10 IFNG
37 12.08 VCAM1 TNF IL1B ICAM1 CD40LG CD40
38 12.07 VCAM1 TNF SELE IL6 IL1B ICAM1
39 12.03 TNF IL6 IL4R IL1B
40 12.02 TNF IL6 IL1B IFNG ICAM1
41
Show member pathways
11.99 IL6 IL4R IL1B IFNG
42 11.98 VCAM1 TNF THBD SELE IL6 IL1B
43 11.95 SELE IL6 IL2 IFNG ICAM1
44 11.92 TNF IL2 IL1B IL10 IFNG
45
Show member pathways
11.91 TNF IL6 IL2 IL1B IL10 IFNG
46 11.9 TNF IL6 IL1B IL10
47
Show member pathways
11.9 TNF IL2 IFNG CD40LG
48
Show member pathways
11.85 TNF CD40LG CD40
49
Show member pathways
11.8 TNF CD40LG CD40
50 11.78 TNF THBD IL6 IL2 IL1B IL10

GO Terms for Plasmodium Vivax Malaria

Cellular components related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.92 VCAM1 TNF THBD SELE IL4R ICAM1
2 extracellular region GO:0005576 9.9 TNF IL6 IL4R IL2 IL1B IL10
3 cell surface GO:0009986 9.73 VCAM1 TNF THBD ICAM1 CD40LG CD40
4 external side of plasma membrane GO:0009897 9.5 VCAM1 TNF THBD ICAM1 CXCL10 CD40LG
5 extracellular space GO:0005615 9.5 VCAM1 TNF THBD SELE IL6 IL4R

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 10.02 VCAM1 ICAM1 CD40LG CD40
2 defense response to virus GO:0051607 10.01 IL6 IFNG CXCL10 CD40
3 positive regulation of protein phosphorylation GO:0001934 10.01 TNF IL2 IL1B IFNG CD40
4 leukocyte migration GO:0050900 10 TNF THBD SELE ICAM1 ANGPT2
5 response to ethanol GO:0045471 9.96 VCAM1 IL2 ICAM1 G6PD
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL1B IL10
7 positive regulation of inflammatory response GO:0050729 9.93 TNF IL2 IL1B IFNG
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.93 TNF IL6 IL1B ICAM1 CD40LG CD40
9 positive regulation of interleukin-6 production GO:0032755 9.92 TNF IL6 IL1B IFNG
10 inflammatory response GO:0006954 9.92 TNF SELE IL6 IL1B CXCL10 CD40LG
11 immune response GO:0006955 9.91 TNF IL6 IL4R IL2 IL1B IL10
12 B cell differentiation GO:0030183 9.9 VCAM1 IL10 CD40LG
13 interferon-gamma-mediated signaling pathway GO:0060333 9.9 VCAM1 IFNG ICAM1
14 response to glucocorticoid GO:0051384 9.89 TNF IL6 IL10
15 regulation of insulin secretion GO:0050796 9.89 TNF IL6 IL1B IFNG
16 positive regulation of interferon-gamma production GO:0032729 9.88 TNF IL2 IL1B
17 positive regulation of interleukin-8 production GO:0032757 9.88 TNF IL6 IL1B
18 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
19 positive regulation of interleukin-1 beta production GO:0032731 9.88 TNF IL6 IFNG
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 TNF IL6 IL2 IFNG CD40
21 positive regulation of cytokine production GO:0001819 9.87 TNF IL10 IFNG
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.87 TNF IL10 DDX39B
23 response to activity GO:0014823 9.87 IL6 IL10 ANGPT2
24 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.86 VCAM1 SELE ICAM1
25 positive regulation of phagocytosis GO:0050766 9.85 TNF IL1B IFNG
26 positive regulation of interleukin-12 production GO:0032735 9.85 IFNG CD40LG CD40
27 protein kinase B signaling GO:0043491 9.85 TNF IL1B CD40
28 B cell proliferation GO:0042100 9.84 IL10 CD40LG CD40
29 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 TNF IL1B IFNG ICAM1
30 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 IL10
31 positive regulation of chemokine production GO:0032722 9.83 TNF IL6 IL4R IFNG
32 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
33 defense response to protozoan GO:0042832 9.81 IL4R IL10 CD40
34 leukocyte cell-cell adhesion GO:0007159 9.8 VCAM1 SELE ICAM1 CD40LG
35 leukocyte tethering or rolling GO:0050901 9.79 VCAM1 TNF SELE
36 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
37 positive regulation of T cell proliferation GO:0042102 9.77 VCAM1 IL6 IL2 IL1B CD40LG
38 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 TNF IL1B IFNG
39 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
40 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.74 TNF IL6 ICAM1
41 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 IL10 IFNG
43 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
44 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL6 IL1B
45 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL2 CD40
46 CD40 signaling pathway GO:0023035 9.72 CD40LG CD40
47 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
48 regulation of immunoglobulin production GO:0002637 9.72 TNF CD40LG CD40
49 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
50 positive regulation of immunoglobulin production GO:0002639 9.71 IL6 IL4R IL2 IL10

Molecular functions related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.46 THBD ICAM1 CD40 ACKR1
2 integrin binding GO:0005178 9.26 VCAM1 IL1B ICAM1 CD40LG
3 cytokine activity GO:0005125 9.23 TNF IL6 IL2 IL1B IL10 IFNG

Sources for Plasmodium Vivax Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....